MedTrace Logo

SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

NCT03801889 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-10-05

No results posted yet for this study

Summary

The purpose of this study is to test the safety and tolerability of SP-420 and it's efficacy in terms of lowering iron in subjects with Beta-thalassemia or other rare anemias who need regular blood transfusions.

Conditions

Interventions

DRUG

SP-420

Self-administered by mouth

Sponsors & Collaborators

  • Abfero Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Ali Taher, MD, PhD · American University of Beirut Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-31
Primary Completion
2022-09-30
Completion
2023-01-31
FDA Drug
Yes

Countries

  • Canada
  • Lebanon
  • Thailand
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03801889 on ClinicalTrials.gov